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a b s t r a c t
Illicit drug use may inﬂuence cognition in non-affective psychosis. Previous studies have shown better
cognition in psychosis with illicit drug use as compared to psychosis only. Possibly, illicit drug using
patients have more transient drug-related cognitive deﬁcits. Thus, the aim of the present study was to
examine cognitive change the ﬁrst weeks after admission to a psychiatric emergency ward, expecting
more cognitive improvement at follow-up in the illicit drug group as compared to psychosis only.
Patients with acute non-affective psychosis with (26%) and without illicit drug use were examined at
baseline (n¼123) and follow-up (n¼67), with alternative forms of the Repeatable Battery for the
Assessment of Neuropsychological Status. Latent Growth Curve models, controlling for cognition at
baseline and age differences between the groups, were used to analyze cognitive change. The illicit drug
using patients showed the largest improvement in cognition, especially among the youngest patients.
Younger patients with non-affective psychosis and illicit drug use showed more cognitive improvement
the ﬁrst weeks after acute psychosis as compared to psychosis only. This suggests that the illicit drug
users constitute a sub-group with less stable cognitive deﬁcits and less cognitive vulnerability.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Extensive use of illicit drugs is common in patients with non-
affective psychosis, typically about 40–50% of patients with psy-
chosis report lifetime substance use disorder (Regier et al., 1990;
Kovasznay et al., 1997; Blanchard et al., 2000; Margolese et al.,
2004). The range of reported substance use disorder is large in
psychosis, however, from 10% to 70%, depending on methodologi-
cal differences and population characteristics (Jimenez-Castro
et al., 2011). Rates of cannabis use have been found to be especially
high; a review reported that median rate for current cannabis use
disorder was 28.6% in ﬁrst-episode and 22.0% for more long-
lasting non-affective psychosis (Koskinen et al., 2010). Substance
use in psychosis has been associated with more hospitalizations,
non-adherence, heightened suicide risk and adverse long-term
clinical outcomes compared to patients with psychosis who do not
use illicit drugs (Talamo et al., 2006; Zammit et al., 2008; Schmidt
et al., 2011; Large et al., 2014; Sara et al., 2014; Tarricone et al.,
2014). Some of the most frequently used illicit drugs, cannabis and
stimulants (Ringen et al., 2008; Helseth et al., 2009; Koskinen
et al., 2010), may induce transient positive psychosis symptoms
and cognitive alterations (Curran et al., 2004; D’Souza et al., 2005,
2009; Smith et al., 2009).
A majority of patients with schizophrenia and non-affective
psychoses have clinical signiﬁcant cognitive deﬁcits (Keefe and
Fenton, 2007; Palmer et al., 2009; Lewandowski et al., 2011), often
depicted as a vulnerability factor that is present also before the
development of psychosis (Woodberry et al., 2008) and in high-risk
populations (Brewer et al., 2005; Woodberry et al., 2010). It is likely,
however, that the use of illicit drugs inﬂuences cognition in psycho-
sis. Experimental studies have shown that the most prominent
psychoactive substance in cannabis, Delta-9-tetrahydrocannabinol
(THC), have an especially strong negative effect on cognition in
individuals with psychosis (D’Souza et al., 2005; Henquet et al.,
2006). Most studies, have found better cognitive functioning in
psychosis patients with lifetime or previous illicit drug use as
compared to psychosis alone (Potvin et al., 2008; Løberg and
Hugdahl, 2009; Rabin et al., 2011; Yucel et al., 2012), although this
has not been consistently shown in all studies (e.g. Wobrock et al.,
2013). Furthermore, for cannabis, superior cognitive functioning in
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the illicit drug using group has been reported in ﬁrst episode
psychosis patients (Rodriguez-Sanchez et al., 2010; Cunha et al.,
2013) and at 10-year follow-up after onset of psychosis (Stirling et al.,
2005), and replicated by means of functional Magnetic Resonance
Imaging (fMRI) (Løberg et al., 2012). Whilst intake of THC has been
associated with transient cognitive deﬁcits (D’Souza et al., 2005,
2009), mixed results for the intake of stimulants have been reported
with both better (Barch and Carter, 2005; Bahorik et al., 2013) and
worse (Meijer et al., 2012) cognitive performance in non-affective
psychosis. It is likely that the effect of both cannabis and stimulants
use on cognition in patients with non-affective psychosis is time-
related (Løberg and Hugdahl, 2009). Possibly, current illicit drug use,
like cannabis, inﬂuence cognition more negatively, while previous
drug use is a marker of a different pathway to psychosis. The illicit
drug using psychotic patients may constitute a sub-group with less
cognitive vulnerability (Løberg et al., 2012; Ferraro et al., 2013); illicit
drug use may have a more temporary inﬂuence on cognition,
generating a short-term cognitive and psychotic breakdown
(Løberg and Hugdahl, 2009). Thus, illicit drug use, like cannabis,
may create transient deﬁcits in cognition paralleling the period of
acute psychosis.
To test this hypothesis, it is necessary to examine the change of
cognitive functioning from the time of an acute psychotic break-
through to the stabilization of psychotic symptoms in patients
with and without drug use. Furthermore, the drug using group
should be abstinent from illicit drugs in the follow-up period to
enable possible cognitive improvement. To accomplish this, only
patients with symptoms of acute psychosis admitted to a psychia-
tric in-patient emergency department were included, and the
patients were followed while hospitalized to minimize use of
illicit drugs. By 4–6 weeks most of the long-term effects of illicit
drug use should be minimized, and most psychosis symptoms
responding to treatment (Sherwood et al., 2006; Szoke et al.,
2008). Follow-up was therefore set to time of discharge from the
acute ward or after 6 weeks at the latest, if not discharged earlier.
This was allowed for both a naturalistic prognostic design and
a reduction of variability in regard to time to follow-up. Further-
more, a brief neuropsychological screening instrument with
alternative forms; the Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS), was used to minimize poten-
tial practice effects (Randolph, 1998; Gold et al., 1999; Beglinger
et al., 2005). Earlier longitudinal studies on cognitive functioning
have usually not addressed the issue of practice effects sufﬁciently
(Goldberg et al., 2007, 2010). Practice effects can be particularly
evident when there are short time intervals between repeated
neuropsychological testing, and the effect seems to be strongest
from baseline to the second testing (Hausknecht et al., 2007;
Bartels et al., 2010). Latent Growth Curve modeling was chosen to
examine cognitive trajectories from baseline to follow-up in order
to minimize the effect of missing data, controlling for the baseline
level in cognitive functioning and varying test–retest intervals.
The aim of the present study was to compare cognitive changes
in non-affective psychosis patients with illicit drug use to cognitive
changes in non-affective psychosis patients with no illicit drug use
after an acute psychotic episode. It was hypothesized that the drug
group would show more improvement in cognitive functioning
from time of admission to a psychiatric emergency ward to time of
discharge from the acute ward or after 6 weeks at the latest.
2. Methods
2.1. Study design
All patients were recruited from an acute psychiatric emergency ward at
Haukeland University Hospital, Bergen, Norway, through an extensive clinical
research project; the Bergen Psychosis Project (BPP). This project was a 24-month,
prospective, rater-blind, pragmatic, randomized, head-to-head comparison of the
effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone (see Johnsen
et al. (2010), for details). Thus, all patients were candidates for oral antipsychotic
drug therapy. The present study used data from the period the patients were
in-patients at the psychiatric emergency ward. Baseline was deﬁned as the time of
admittance to the ward, and follow-up was deﬁned as time of discharge from the
acute ward or after 6 weeks at the latest, if not discharged earlier, except for three
patients that for practical reasons were followed-up between 7 and 11 weeks. The
mean time period from baseline to follow-up was 4 weeks (M¼4.03, S.D.¼2.13,
Mdn¼3.71). The ﬁrst inclusion of patients to the present study took place the 9th of
March 2004 and the last patient was included the 13th of January 2009. The project
was approved by the Regional Committee for Medical Research Ethics and the
Norwegian Social Science Data Services. The Regional Committee for Medical
Research Ethics allowed eligible patients to be included before informed consent
was provided, thus entailing a clinically relevant representation in the study.
2.2. Subjects
2.2.1. Inclusion criteria and sample characteristics
Criteria for inclusion were symptoms of active non-affective psychosis, deter-
mined by a score of four or over on one or more of the items Delusions,
Hallucinatory behavior, Grandiosity, Suspiciousness/Persecution, or Unusual
thought content from the Positive and Negative Syndrome Scale (PANSS) (Kay
et al., 1989). Patients with affective psychoses and drug-induced psychosis were
excluded, and all patients met the ICD-10 diagnostic criteria (WHO, 2004) for
schizophrenia, schizoaffective disorder, acute and transient psychotic disorder,
delusional disorder and non-organic psychotic disorder. The diagnoses were
determined by psychiatrists or specialists in clinical psychology. Patients were
excluded if they were not able to understand Norwegian, had a history of head
injury or mental retardation. In addition, patients under the inﬂuence of illicit
drugs during testing were excluded. There were 123 patients at baseline and 67
patients at follow-up. Demographic, clinical and cognitive characteristics by group
and time of assessment are provided in Table 1.
2.2.2. Drug groups
Information on illicit drug use was based on the Clinician Drug Use Scale
(CDUS) and alcohol use was based on the Clinician Alcohol Use Scale (CAUS) (Drake
et al., 1990). The scales have similar structures. The drug use scale rates clinically
signiﬁcant illicit drug use in severe mental illness on a scale from 1 to 5 ranging
from abstinence (1), use without impairment (2), abuse (3), dependent (4), and
severe dependence (5) the last 6 months (Drake et al., 1996). The patients’ drug use
in the present study was rated by a trained psychiatrist, and the threshold was set
at “use without impairment”. The psychiatrist used all available information over
the 6 last months when evaluating the illicit drug use. The Clinical Drug Use scale
has shown excellent reliability and increase of validity when multiple sources are
used for rating severity of drug use, in addition to high sensitivity and speciﬁcity
(Drake et al., 1990). Patients were split into two groups at baseline according to the
presence of drug use. A psychosis group without drug use (n¼91), and a group
with both psychosis and concurrent drug use (n¼32). To further decrease false
negative drug users all the patients’ clinical records were carefully examined by a
trained psychiatric research nurse for use of cannabis as a marker of drug use, as it
is possible that cannabis use could be underreported (Bahorik et al., 2014). All 32
patients in the psychosis group with drug use had a lifetime history of cannabis
use. In addition, the distribution of additional drug use as reported by use of Drug
Use Scale was the following: stimulants; n¼6, stimulants, sedatives, hypnotic,
anxiolytic; n¼3, opiates and stimulants; n¼2, stimulants, sedatives, hypnotic,
anxiolytic, opiates; n¼1. There were 72 urine tests administrated at baseline, seven
of these patients tested positive on cannabis, two on amphetamines and one on
opiates, 33 on benzodiazepines. As part of the admission to the psychiatric
emergency ward, hospital staff examines the patients’ property in search for
substances. Urine tests are administrated if an in-patient appears intoxicated or
is suspected to have been using illicit drugs. In the psychosis groups with and
without illicit drug use the distribution of the ICD-10 primary psychosis diagnosis
was the following at baseline: schizophrenia spectrum; 62.5%, 39.5%, acute and
transient psychotic disorders; 34.4%, 49.5%, and non-organic psychotic disorders;
3.1%, 11.0%, respectively. At 1 month follow-up the distribution of psychosis
diagnosis was similar to baseline distribution in the psychosis groups without
and with illicit drug use: schizophrenia spectrum; 62.6%, 38.5%, acute and transient
psychotic disorders; 31.2%, 51.9%, non-organic psychotic disorder; 6.2%, 9.6%.
2.3. Assessments
2.3.1. Cognitive assessments
To assess cognitive impairments the Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS) (Randolph, 1998) was administrated at baseline
and follow-up to assess cognitive impairments in patients with psychosis by
trained psychiatric research nurses. RBANS is a cognitive screening instrument
that can be used to examine cognitive change when administrated successively
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since it has alternative forms. It takes about 30 min to administrate the 12 subtests
that make up the test battery, making it suitable also for acute psychotic patients
who may have less endurance in a test situation. RBANS measures the following
domains: Immediate Memory, Visuospatial/Constructional Ability, Language, Atten-
tion, Delayed Memory, as well as a global measure, Total Scale (Randolph, 1998).
These cognitive functions are of particular interest in psychosis research, and it has
been demonstrated that RBANS, as a screening instrument, has good sensitivity to
typical cognitive deﬁcits in schizophrenia, in addition to good validity and
reliability (Gold et al., 1999; Hobart et al., 1999; Wilk et al., 2004; Holzer et al.,
2007). RBANS Total Scale has the best test–retest reliability as opposed to the
speciﬁc domains, except from Attention, which also have demonstrated good
test–retest reliability (Gold et al., 1999; Wilk et al., 2002). The RBANS total t-score
was therefore chosen for the analyses.
2.3.2. Clinical assessments
All clinical assessments were performed at baseline and follow-up by trained
psychiatrists. Symptoms were assessed with the PANSS (Kay et al., 1989), and there
were no systematic differences among the raters as shown by excellent inter-rater
reliability coefﬁcients (0.92). Global Assessment of Functioning scale-Split Version,
Function Scale (GAF-F) was used as an estimate of general functioning (Karterud
et al., 1998).
2.4. Statistical analysis
SPSS version 20 was used for descriptive statistics, cross-tabulations with
χ2-test, and t-tests of group differences (SPSS, 2011). Latent Growth Curve models
were analyzed with the Mplus program, version 7.11 (Muthén and Muthén, 2013).
ANOVA repeated measure is based on the listwise deletion method, assumes equal
test–retest intervals and individual variations in change are not addressed (Nayak
Savla et al., 2006). Latent Growth Curve modeling was used to analyse individual
and mean level and change in RBANS total t-score. This is a critical feature as
cognitive functioning in patients with schizophrenia is heterogeneous and patients
may have different cognitive development trajectories; some patients’ performance
on neuropsychological tests is stable, whilst others’ performance change over time
(Barnett et al., 2007; Lewandowski et al., 2011). Change between two measurement
time points, as in the present study, is a difference score model (Raykov, 1993;
Duncan et al., 2006). Individual changes over time may be non-linear. This is,
however, not possible to explore within the present design. Therefore the
estimated model assumes linearity, which also is illustrated in the model generated
ﬁgure. Because of only two measurement points the residuals had to be
pre-speciﬁed in order to identify the model (Stoolmiller, 1995). Mplus allows
unequal individual time-spaced observations to be analyzed (Muthén and Muthén,
2013), and the measurement of time was speciﬁed as weeks. This makes it
particular advantageous when examining cognitive changes over time in the
present naturalistic design. The default estimator for Latent Growth Curve model-
ing is maximum likelihood with robust standard errors (MLR), which is robust for
non-normal data (Muthén and Muthén, 2008; Kline, 2010).
Mplus models may use all available data and will in this way minimize the
effect of missing data (Duncan and Duncan, 2004; Bollen and Curran, 2006). Out of
32 subjects in the drug use group and 91 subjects in the group without drug use, 16
and 51 contributed at the follow-up occasion. The full information data analysis
method used give improved statistical power and generalizability to the results
relative to what would be the case if the ordinary listwise deletion method had
been used for data analysis. This means that all patients at baseline gave
information to the baseline part of the statistical model. Besides, the contribution
rate at follow-up is very similar in the two groups (non-drug: 56% and drug: 50%).
The standard Latent Growth Curve models assume missing data to be missing at
random (Muthén and Muthén, 2013). In order to examine the validity of this
assumption, independent t-tests were used to examine possibly differences in all
baseline demographic, clinical, and cognitive characteristics in the sample that was
retested and those that dropped out from the study. The only differences that
emerged were in relation to a signiﬁcantly higher score on Delayed Memory and
Attention for the retested sample, (M¼40.82, S.D.¼11.53; M¼31.21, S.D.¼8.99), as
compared to drop-outs (M¼35.00, S.D.¼12.68; M¼27.89, S.D.¼8.72), respectively,
t(116)42.03, Po0.05 for both comparisons. The overall lack of differences in
demographic, clinical, and cognitive characteristics between the follow-up group
and patients t baseline only indicates that the drop-outs are “missing at random”
(McKnight et al., 2007).
Unconditional Latent Growth Curve models were ﬁrst analyzed, then Group
(Psychosis group with and without drug use), Age and the interaction term
between Group and Age were entered as predictors. A dummy contrast variable
was used for group comparison (Pedhazur and Schmelkin, 1991). The interaction
term between Group and Age was included into the statistical model in order to
account for the age difference (mean and variance) in the two groups and to
explore if differences between the groups were found to be dependent on the age
levels (Cohen et al., 2003). Integrating interaction terms into the model is standard
procedure in order to account for heteroscedasticity (Cohen et al., 2003). The Age
variable was kept as a continuous variable, as categorizing the variable results in
reduced statistical power (Royston et al., 2006) and small sample sizes in sub-
groups. If not contributing statistically signiﬁcant, the interaction terms and the
Age variable were removed from the models in a backward hierarchical procedure
Table 1
Mean (S.D.) demographic, clinical and cognitive data by group.
Baseline Follow-up
Without drug use n¼91 With drug use n¼32 Without drug use n¼51 With drug use n¼16
Group distribution % 74.0% 26.0% 76.1% 23.9%
Men % 61.5% 84.4% n 58.8% 87.5% n
Age 37.83 (12.82) 26.54 (6.23)nnn 37.78 (13.41) 25.74 (5.48)nnn
Education (years) 13.01 (3.12) 12.42 (2.83) 12.92 (2.99) 13.30 (3.37)
Clinician Drug Use Scale 1.02 (0.14) 2.23 (0.95)nnn
Clinician Alcohol Use Scale 1.83 (0.52) 2.16 (0.45) n
Medication (DDD) 1.16 (0.57) 0.94 (0.45)
PANSS
Delusions 4.66 (1.10) 4.47 (1.14) 3.00 (1.44) 3.13 (1.09)
Unusual thought content 2.42 (1.49) 2.72 (1.73) 1.47 (0.88) 1.88 (1.09)
Hallucinatory behavior 3.43 (1.74) 4.03 (1.40) 2.25 (1.66) 2.06 (1.12)
Grandiosity 1.43 (1.09) 2.19 (1.64) n 1.08 (0.56) 1.94 (1.57)n
Suspiciousness 4.29 (1.59) 4.13 (1.29) 2.67 (1.60) 2.63 (1.26)
Positive scale 19.66 (3.93) 21.34 (5.38) 12.86 (4.36) 14.38 (4.33)
Negative scale 19.67 (7.37) 19.09 (8.66) 14.80 (6.44) 16.13 (7.03)
Gen. psychopath.scale 33.67 (6.08) 36.06 (7.13) 25.88 (7.09) 25.81 (2.97)
Total 73.00 (12.61) 76.50 (16.38) 53.55 (15.35) 56.31 (9.26)
GAF function score 31.01 (5.03) 30.84 (3.99) 39.44 (8.50) 37.00 (4.72)
RBANS t-scores
Immediate memory 35.95 (11.20) 34.48 (9.07) 40.02 (10.84) 38.33 (10.52)
Visuospatial/constructional 47.52 (12.64) 48.55 (12.83) 48.45 (12.08) 47.80 (12.42)
Language 40.82 (7.77) 38.52 (8.61) 46.27 (7.77) 46.20 (10.58)
Attention 30.32 (9.36) 27.61 (7.59) 34.49 (9.26) 33.07 (11.85)
Delayed Memory 38.57 (12.61) 36.42 (11.82) 41.96 (12.21) 40.27 (12.93)
Total 35.10 (10.04) 33.32 (8.69) 42.24 (7.52) 41.13 (8.37)
Note. S.D.¼Standard Deviation. DDD¼Deﬁned Daily Dose. PANSS¼The Positive and Negative Syndrome Scale for Schizophrenia. GAF¼Global Assessment of Functioning
Scale. RBANS¼The Repeatable Battery for the Assessment of Neuropsychological Status.
n Signiﬁcant at the Po0.005 level.
nnn Po0.001.
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(Cohen et al., 2003). The Gender and the GenderGroup interaction variables were
tested in an additional model. The triple interaction between Group, Age, and
Gender was included to even more fully account for the data heterogeneity with
regard to group differences. The term tests for gender-speciﬁc group differences at
different age levels. Multicolinearity in interaction analyses was solved by mean
centering of the age variable (Pedhazur and Schmelkin, 1991; Cohen et al., 2003).
3. Results
3.1. Demographic, clinical, and cognitive characteristics
The demographic, clinical, and cognitive characteristics from
Table 1 were satisfactorily normal distributed to allow for the use
of parametric analyses. To examine group differences for these
variables at baseline, chi-square tests and t-tests were used for the
categorical and continuous variables, respectively, see Table 1
for details. The groups differed in regard to Gender and Age,
χ² (1, N¼123)¼5.62, Po0.05, and t(108)¼6.57, Po0.001, respec-
tively. There were more men in the psychosis group with illicit
drug use compared to the psychosis group without, and patients in
the psychosis group with illicit drug use (M¼26.54, S.D.¼6.23)
were younger than the non-users (M¼37.83, S.D.¼12.82). In
addition, at baseline the psychosis group with illicit drug use
had a higher score on Grandiosity (M¼2.19, S.D.¼1.64), t(41)¼
2.44, Po0.05, compared to psychosis group without illicit drug
use (M¼1.43, S.D.¼1.09). The psychosis group with illicit drug use
had signiﬁcantly higher ratings on the Clinical Drug Use Scale
(M¼2.23, S.D.¼0.95), t(30)¼6.98, Po0.001, and Clinical Alcohol
Use Scale (M¼2.16, S.D.¼0.45), t(12)¼3.16, Po0.05, compared to
the group without (CDUS; M¼1.02, S.D.¼0.14), (CAUS: M¼1.83,
S.D.¼0.52). There were no differences in the distribution of a
schizophrenia spectrum diagnosis and an acute transient diagnosis
in the respective groups χ² (1, N¼112)¼2.85, Po0.05.
3.2. Change in cognition
In the unconditional growth curve model (without inclusion of
predictors) the mean baseline score was 34.71 (Po0.05) and the
mean change was 1.10 (Po0.05). In addition, there was statisti-
cally signiﬁcant individual variation at the baseline level (inter-
cept) (92.40, Po0.05) and in cognitive change per week (slope)
(7.36, Po0.05). A negative relation between baseline level
and change per week emerged (covariance: 7.50, r¼0.29,
Po0.05), which indicates a steeper increase in RBANS total
t-scores among patients displaying a lower baseline score on
RBANS total (estimated increase at different baseline levels: mean:
1.11; minus 1 S.D.: 1.89; and plus 1 S.D.: 0.33). This ﬁnding
supports the need for statistical analyses controlling for this effect.
The Fig. 1 presents the model estimated results from the Latent
Growth Curve models, illustrating the cognitive change in the
two groups over time and dependent on Age. To illustrate how
cognitive change across different age levels varies in the two
groups, ages 25, 35 and 45 are represented as different lines. This
model, which controlled for RBANS total t-score at baseline,
showed a larger increase of the total t-score per week in the
psychosis patients with illicit drug use (group effect: b¼2.00,
Po0.05), especially among younger patients (GroupAge inter-
action: b¼0.29, Po0.05).
The analyses including Gender and Gender interaction with
Group and Age did not give any statistically signiﬁcant results. The
re-estimated model without the triple interaction gave the follow-
ing results for the change factor: Group: b¼2.53 (Po0.05); Age:
b¼0.02 (P40.05); GroupAge: b¼0.29 (Po0.05); Gender:
b¼1.20 (P40.05); and GroupGender: b¼1.25 (P40.05).
To better understand the effect of age on cognitive change in
the psychosis group with illicit drug use, additional statistical
analyses were performed, focusing on symptoms, type of illicit
drug use and diagnosis as potential confounders. Pearson correla-
tion analyses were used to examine how age in the psychosis
group with illicit drug use was related to symptoms as measured
by the PANSS subscales. Simple linear regression analyses were
used to examine how Age was related to multiple drug use versus
single drug use, and having a schizophrenia diagnosis as opposed
to an acute or transient psychosis diagnosis in the psychosis group
with illicit drug use. There were negative associations between
Age and the PANSS negative subscale, r¼0.37; PANSS general
psychopathological subscale, r¼0.38; and PANSS total score,
r¼0.38, at baseline, all Po0.05. No associations emerged
between Age and Type of drug use and Diagnosis (having a
schizophrenia diagnosis as opposed to an acute psychosis
diagnosis).
4. Discussion
A general cognitive improvement emerged in non-affective
psychosis with and without illicit drug use in the ﬁrst month after
an acute psychotic episode. As hypothesized, the psychosis group
with illicit drug use showed the largest increase in performance on
the global measure of cognitive functioning from baseline to
follow-up, especially among the youngest patients in this group.
No signiﬁcant differences in cognitive functioning were found at
baseline between the groups in this study. However, a larger
increase in cognitive functioning emerged in the psychosis group
with illicit drug use as compared to the group without from
admission to follow-up. This indicates that the cognitive recovery
process is more prominent in the illicit drug using psychosis group
in the acute phase as opposed to the non-affective psychosis only
group. Possibly, patients with non-affective psychosis and a
history of illicit drug use, like for instance cannabis, originally
have a superior cognitive functioning (Løberg and Hugdahl, 2009;
Yucel et al., 2012). Conceivably, use of illicit drugs can induce
transient cognitive deﬁcits, mimicking the cognitive vulnerability
that characterizes patients with schizophrenia at group level
(Løberg and Hugdahl, 2009). The results from this study, with
larger cognitive changes in the psychosis group with illicit drug
use, are in line with this assumption. Thus, the cognitive deﬁcits
Fig. 1. Model estimated change in RBANS total t-score from baseline to follow-up
in the psychosis groups with and without illicit drug use by age.
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initially in the acute psychosis phase may be attributed to the
effects of illicit drugs, like cannabis.
The analyzed interaction model accounted for age differences
in the two groups and showed the group difference to be stronger
for younger patients. This means that the younger patients in the
psychosis group with illicit drug use had the largest cognitive
change in the acute phase, and younger age was not related to
polydrug use or having a schizophrenia diagnoses as opposed to
an acute and transient psychosis diagnosis in the psychosis group
with illicit drug use group. A plausible explanation for a larger
cognitive change among the younger illicit drug using patients is
that their neurocognitive set-up is more resilient and ﬂexible;
their younger brains may have a larger capacity for plasticity (Kolb
and Robbin, 2011). Accordingly, the recovery process of the brain
functioning in the acute phase is larger among these patients.
However, one cannot rule out the possibility of a selection bias.
Theoretically the younger patients in this study could represent a
better functioning cognition sub-group. The association between
younger age and higher scores on the PANSS negative and general
psychopathology subscales, and thus higher PANSS total scores, in
the psychosis group with illicit drug use, implies that the younger
illicit drug using patients have more, not less, symptoms at
admission. However, in spite of more symptoms at baseline the
youngest illicit drug using patients have the most improvement on
the neuropsychological tests in the acute phase. Interestingly, this
effect of age has been reported previously; a meta-analysis by
Potvin et al. (2008) found that the effect of better global cognition
in schizophrenia patients with mixed substance use or cannabis
use decreased with increased age. Thus, it is important to be
aware of the effect of age in relation to cognitive functioning when
drawing conclusions about cognition.
Use of illicit drugs like cannabis and amphetamines, may have
led to disturbances in dopaminergic and endogenous cannabinoid
system and transient cognitive deﬁcits, which ultimately have
resulted in expression of a psychotic disorder (Di Forti et al., 2007;
Bossong and Niesink, 2010; Kuepper et al., 2010). This is supported
by the fact that having a drug use disorder, in particular cannabis
and amphetamines use disorder (Callaghan et al., 2012), or earlier
cannabis use, is a risk factor for developing schizophrenia in a dose
dependent manner (Andreasson et al., 1987; Henquet et al., 2005;
Moore et al., 2007). Thus, illicit drug-using patients may have
become psychotic through an alternative etiological pathway
Løberg and Hugdahl, 2009; Løberg et al., 2012). Supporting this,
less neurological soft signs (Bersani et al., 2002; Stirling et al.,
2005; Ruiz-Veguilla et al., 2012) and better social and leisure
functioning and more social contacts among drug using patients
with schizophrenia, as compared to psychosis patients without
illicit drug use, have also been found (Salyers and Mueser, 2001).
In addition, non-affective psychosis patients with cannabis use
seem to have a higher premorbid IQ compared to those without
illicit drug use (Leeson et al., 2012). Furthermore, studies have
generally reported an earlier onset of psychosis among cannabis
using patients with schizophrenia (Large et al., 2011; Leeson et al.,
2012; Myles et al., 2012; Di Forti et al., 2013; Donoghue et al.,
2014), also suggesting an alternative etiological pathway. Use of
illicit drugs, like cannabis and amphetamines seems to have an
additive negative effect on brain functioning, and in some
individuals the threshold for developing psychosis is lowered,
presumably depending on the brains ability to tolerate the effects
of drugs, amount of drugs taken and genetic and cognitive
vulnerability.
The present study is a naturalistic prospective study integrated
in clinical practice. This increases the generalizability and clinical
relevance of the study, while at the same time decreases the ability
to control for confounders and the ability to create a more
homogenous drug user group, since multiple drug use seems to
be the norm. It may therefore be difﬁcult to attribute the
differential effects on cognition to a particular illicit drug. Con-
founders have been minimized by controlling for group differences
by statistical procedures, but it is a weakness of this study that age
onset of psychosis and number of psychotic episodes were not
recorded, this was also the case with frequency and duration of
illicit drug use. Methodological strengths of the present study
were particularly that the patients were hospitalized during the
follow-up to minimize drug use and that that neuropsychological
screening instrument had alternative forms to avoid practice
effects. The present study did not include a control group of
healthy individuals.
Cognitive functioning has been shown to predict functional
everyday outcomes, like work participation, better than positive
symptoms (Green, 1996; Ventura et al., 2009). RBANS total score
has also been shown to be strongly related to work participation in
patients with schizophrenia (Gold et al., 1999). Even though a
general cognitive improvement took place in both groups, indicat-
ing that neuropsychological functioning in the acute psychosis
phase is not stable, better cognition in particularly the younger
psychosis patients that are using illicit drugs emerged. This may
have positive clinical implications, suggesting a potential for better
functional outcome. It seems plausible however, that a better
prognosis is dependent on abstinence from illicit drugs (Mullin
et al., 2012; Gupta et al., 2013). In line with this, worse cognitive
functioning has been associated with continuous use of illicit
drugs in psychosis (Rabin et al., 2012). A parallel focus on illicit
drug use in the treatment of psychosis is therefore beneﬁcial also
with cognition in mind.
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